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Overview of pathogenesis of systemic sclerosis
Abstract
The aetiology of SSc is subject to ongoing research, as the precise events that underlie the development
of this disease remain unclear. The pathogenesis is known to involve endothelium, epithelium,
fibroblasts, innate and adaptive immune systems and their component immunological mediators.
Endothelial cell damage may be the initiating factor, but the precise triggering event(s) remain elusive.
Angiogenesis also appears to be dysregulated. Vasculopathy shows similarities in different organs (e.g.
pulmonary arterial hypertension, renal disease, digital tip ulcers). Endothelin-1 is a potent mediator of
vasculopathy, and hence represents a highly relevant target for intervention of vascular features in SSc.
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ABSTRACT 
The aetiology of systemic sclerosis (SSc) is subject to ongoing research, as the precise 
events that underlie the development of this disease remain unclear. The pathogenesis is 
known to involve endothelium, epithelium, fibroblasts, innate and adaptive immune systems 
and their component immunological mediators. Endothelial cell damage may be the initiating 
factor, but the precise triggering event(s) remain elusive. Angiogenesis also appears to be 
dysregulated. Vasculopathy shows similarities in different organs (e.g. pulmonary arterial 
hypertension, renal disease, digital tip ulcers). Endothelin-1 is a potent mediator of 
vasculopathy, and hence represents a highly relevant target for intervention of vascular 
features in SSc. 
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INTRODUCTION 
The aetiology of systemic sclerosis (SSc) is currently an expanding area of study, since the 
exact nature of the events underlying this disease remains unclear [1]. SSc may be initiated 
in the vasculature, with evidence suggesting that some morphological changes may be 
apparent before disease onset [1]. The pathological events in SSc may include impaired 
communication between endothelial cells, epithelial cells and fibroblasts; lymphocyte 
activation; autoantibody production; inflammation; and connective tissue fibrosis [1]. These 
events result in an accumulation of constituents of the extracellular matrix (ECM), which 
replaces the normal tissue architecture, which in turn can culminate in organ failure. This 
review will focus on the potential role of the epithelium, and the roles of fibroblasts and 
immunological mediators in the pathogenesis of SSc. In addition, this review will consider the 
mediators of tissue remodelling which are associated with the hallmark vasculopathy of SSc. 
 
THE POTENTIAL ROLE OF THE EPITHELIUM 
The epithelium can be found widespread throughout the body, as the outer covering of the 
skin, and lining both internal organs and body cavities (e.g. mucous membranes, gut and 
lungs). Consequently, it has an extensive range of functions that include secretion, 
absorption, protection, transcellular transport, sensation detection and selective permeability. 
Following tissue injury, the epithelium plays a critical role in repairing wounds and re-
surfacing tissue. In patients with SSc, however, there is evidence that this regeneration may 
be dysregulated. 
Many epithelial-derived factors influence the behaviour of fibroblasts, with some 
soluble mediators known to exhibit pro-fibrotic activities, including transforming growth 
factor-beta (TGF-β) and endothelin-1 (ET-1) (Table 1) [2, 3]. There is also evidence that 
epithelial-to-mesenchymal transdifferentiation (EMT) occurs in lung fibrosis [4, 5], and this 
process is known to be influenced or mediated by TGF-β, and potentially ET-1 [4–6]. 
Page 3 of 23 
Pathogenesis of SSc 
During EMT, epithelial cells lose cell–cell attachment, alter polarity, display specific 
surface markers and can undergo cytoskeletal remodelling to exhibit a mesenchymal 
phenotype [4]. Studies in vitro have shown that alveolar epithelial cells can transdifferentiate 
into mesenchymal cells. Tissue staining and transgenic animal studies have shown that 
alveolar epithelial cells can co-express markers of both epithelial and mesenchymal cells, 
including cadherin and alpha-smooth muscle actin (α-SMA) [5]. In addition, in the murine 
bleomycin-induced lung fibrosis model fibrosis is preceded by epithelial injury. These findings 
suggest that the epithelium might play an important role in the pathogenesis of SSc, at least 
for some specific organ manifestations such as lung fibrosis (Figure 1).  
 
THE ROLE OF FIBROBLASTS AND THE IMMUNE SYSTEM 
The role of fibroblasts 
Fibroblasts maintain the structural integrity of connective tissue, secreting fibrillar 
procollagens, fibronectin and regulating the turnover and composition of the ECM via highly 
specific proteases such as collagenase. Different subtypes of fibroblasts exist and can 
perform a variety of functions in different locations (e.g. papillary fibroblasts, dermal papilla 
fibroblasts, myofibroblasts). Although morphologically similar, these different fibroblast 
subpopulations are distinguishable by their gene expression profiles and functional activities 
[7, 8]. For example, whilst papillary fibroblasts produce thin collagen bundles and have a 
high rate of proliferation, reticular fibroblasts produce thick collagen bundles and abundant 
versican, and promote rapid lattice contraction [9]. Following tissue injury, quiescent 
fibroblasts are activated during the wound healing and inflammation phase, producing 
granulation tissue and a provisional matrix, process that is subsequently reversed to remodel 
the scar. In human disease such as hypertrophic keloid scarring or SSc this scar tissue is not 
correctly terminated or remodelled resulting in excessive scar formation.  
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 Fibroblasts can be categorised according to different stages of differentiation [10], as 
well as their levels of collagen production [11]. In SSc patients, activated fibroblasts are 
responsible for the development of fibrosis and accumulation of ECM molecules. These 
fibroblasts are characterised by an overproduction of collagen and the induction of collagen 
modifying enzymes. 
The gene expression profile of fibroblasts is influenced by their environment [12]. For 
instance, quiescent fibroblasts express ET-1 and intercellular adhesion molecule-1, whereas 
the fibroblasts subject to mechanical stress may express α-SMA, TGF-β and ECM genes. The 
phenotype of SSc fibroblasts is comparable to that of fibroblasts that have been exposed to 
excessive signalling by TGF-β, which suggests a potential underlying mechanism [13, 14]. 
Activated fibroblasts may be derived from a number of origins. Precursor or 
progenitor cells may be recruited from the bone marrow or circulation, and resident cells 
may be recruited locally from the surrounding tissue. Although activated, these fibroblasts 
may not be terminally differentiated and in cell culture they can cease to exhibit an activated 
phenotype after several passages. 
Activated fibroblasts in SSc may be derived from a number of origins [15]. 
Mesenchymal precursor cells may be recruited from the bone marrow via the circulation. 
Resident tissue-specific precursors may also be utilized from the surrounding tissue directly. 
Quiescent fibroblasts can be activated by different mechanism(s) including: (i) direct cell–cell 
contact, (ii) stimulation by soluble mediators following induction of the appropriate receptor 
expression – including TGF-β, connective tissue growth factor (CTGF), platelet-derived 
growth factor (PDGF) or ET-1 [13, 16, 17] – or by (iii) modulation of cell–matrix interactions. 
For example, ECM contraction modulates the activity of mediators such as TGF-β, and 
fibroblasts may also be activated by attachment to the ECM and the resultant mechanical 
tension, which can contribute to a persistent activation state [18]. Altered gene expression in 
SSc fibroblasts, such as the expression of cartilage oligomeric matrix protein and other key 
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ECM components, is also likely to lead to a disturbed macromolecular arrangement of ECM 
molecules [19, 20]. These findings suggest a major role for fibroblasts in the pathogenesis of 
SSc (Figure 2). 
 
The role of immunological mediators 
The immune system is also implicated in the pathology of SSc. Activated lymphocytes and 
autoantibodies are detectable in SSc patients. Elevated levels of growth factors (including 
TGF-β, CTGF, vascular endothelial growth factor [VEGF], fibroblast growth factor), 
interleukins (including IL-2, IL-4, IL-6, IL-10, IL-13), chemokines and cytokines (including 
monocyte chemoattractant protein-1 [MCP-1], IL-8, thymus and activation-regulated 
chemokine, fractalkine and TNF-α) are detectable in this disease. 
 In patients with SSc, activated T lymphocytes are detectable in both the circulation 
and the affected organs (skin and lung). In the circulation, soluble IL-2 receptor levels 
correlate with the extent of skin fibrosis [21] and there is evidence for clonal expansion of T 
cells [22]. In the skin, oligoclonal expansion is observed [23], and there is enhanced 
transendothelial migration of CD4+ T cells [24]. 
The expression of CD19 on the circulating B cells of SSc patients may be increased 
[25], as may the expression of CD80 and CD86 on memory B cells [26]. Comparison of the 
cell type composition and gene expression profiles in skin biopsies from SSc patients with 
normal individuals has revealed clear differences, including infiltration of B lymphocytes into 
affected skin [19]. In the tight skin mouse model of SSc, experimental B cell depletion 
suppresses skin fibrosis and down-regulates Th2 cytokines in the skin [27], which suggests a 
pathological role for B cells in skin fibrosis. 
 The majority of patients with SSc exhibit circulating levels of highly specific 
autoantibodies; One autoantibody group are directed against nuclear antigens 
(topoisomerase, RNA polymerase) whereas the others may have a putative pathogenic role, 
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This latter group includes anti-endothelial cell antibodies, which are estimated to occur in 
44–84% of SSc patients and may induce apoptosis [28–31]. Anti-fibrillin-1 antibodies are 
detectable in >50% of SSc patients and can activate fibroblasts and stimulate release of 
TGF-β. Antibodies to matrix metalloproteinases (MMP)-1 and -3 may also occur in a high 
proportion of patients, preventing the degradation of excessive collagen. Stimulatory anti-
PDGF receptor antibodies are detectable in SSc patients and are potentially pathogenic [16]. 
These autoantibodies may stimulate normal fibroblasts via Ha-Ras pathways, generate 
reactive oxygen species cascades to induce collagen I production and convert resting 
fibroblasts into activated myofibroblasts. Altered B cell function may therefore be a key link 
between autoimmunity and fibrosis (Figure 3). 
 
VASCULOPATHY in SSc 
In patients with SSc, vascular remodelling is dysregulated. In these patients, vasculopathy 
may result from a disrupted or inappropriate repair process following endothelial cell insult or 
injury. These patients may exhibit up-regulation of vasoconstrictive, thrombogenic, mitogenic 
and proinflammatory factors, and down-regulation of vasodilatory, antithrombogenic and 
antimitogenic factors. This results in vasculopathy characterised by vasoconstriction, 
adventitial and intimal proliferation, inflammation and thrombosis. 
 Vasculopathy involves all layers of the vessel wall, and is characterised by fibrotic 
intimal hyperplasia [32]. As a result, vessels lose their elasticity and become narrower. In 
time, the arterial intima may thicken and occlusion of the small arteries can facilitate the 
formation of in situ thrombosis. Although the vasculopathy of SSc clearly shows organ-
specific features, there are a number of similarities in the pathogenesis and morphology. 
Fibrosis typically begins in the media of medium-sized arteries, extending into the intima and 
adventitia and disrupting elasticity. The typical plexiform lesions of pulmonary arterial 
hypertension, comprising endothelial cells and myofibroblasts, can occur at all stages of 
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development and healing. In renal arteries of patients with scleroderma renal crisis [33], 
there is the characteristic overgrowth of the endothelium and deposition of scar tissue in the 
blood vessels [34]. In digital ulceration associated with SSc, vascular remodelling leads to 
progressive occlusion of the blood vessels. Together with the reduced capillary density, this 
results in hypoxia, necrosis and tissue loss [35]. 
 
The processes underlying vasculopathy 
Vascular remodelling appears to be preceded by endothelial dysfunction. Consistent evidence 
suggests that microvascular endothelial cell activation and damage is ubiquitous and occurs 
early in SSc. Activated endothelial cells express adhesion molecules, which in part, promote 
perivascular inflammatory infiltrates by enabling the transmigration of inflammatory cells 
through the endothelium. Platelets are also activated. 
 The identity of the initial trigger remains elusive [36]. Hypotheses for the method of 
primary activation of endothelial cells in SSc include autoantibodies showing cross-reactivity 
between cytomegalovirus (CMV) epitopes and specific surface molecules of endothelial cells, 
inducing apoptosis. However, this is unlikely to be the sole aetiological factor, since CMV is 
ubiquitous in the normal population. Anti-endothelial cell antibodies can also activate 
endothelial cells, inducing the production of adhesion molecules and cytokines such as IL-1 
and TNF-α. However, anti-endothelial cell antibodies are detected in a variety of vascular 
diseases and specific epitopes and mechanisms have not been clarified in SSc. Oxidative 
stress and the presence of elevated level of reactive oxygen species (ROS) has also been 
suggested to be an essential element in the early vascular pathogenesis in SSc, but the 
precise source of the ROS remains unknown. 
 Whatever the primary cause of the initial activation, ongoing activation inevitably 
results in endothelial cell damage. Apoptosis is an early event, and, if endothelial cells are 
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not replaced by new cells, capillary breakdown and the typical clinical manifestations of 
vasculopathy can result. 
 A physiological reaction pattern to capillary breakdown and resulting tissue hypoxia is 
angiogenesis, a finely balanced process involving both angiogenic and angiostatic factors. In 
patients with SSc, angiogenesis become dysregulated. Angiogenic factors, including PDGF, 
VEGF, ET-1, TGF-β, MCP-1 and urokinase-type plasminogen activator receptors are up-
regulated in SSc, despite the lack of sufficient angiogenic responses in ischemic tissues of 
SSc patients. 
VEGF is over-expressed throughout the dermis and epidermis, including fibroblasts 
and perivascular cells [37]. VEGF receptor-1 (VEGFR-1) and VEGFR-2 are also up-regulated 
[37]. However, while VEGF is one of the strongest angiogenic factors known in biology, its 
duration of expression is of critical importance: an uncontrolled, chronic over-expression, as 
in SSc, might lead to deleterious effects rather than promote the formation of new vessels. 
Alternatively, the up-regulated angiogenic factors could be overwhelmed by an even greater 
up-regulation of angiostatic factors such as angiostatin and endostatin [38, 39]. At present, 
data describing the dysregulation of angiogenic homeostasis are incomplete and need further 
research. 
 
The relationship between blood vessels, endothelium, and pericytes 
Small blood vessels comprise two cell types: endothelial cells and their attendant pericytes. 
To date, vascular research in SSc has been focussed on the role of the endothelial cells in 
SSc pathogenesis, with the pericyte being largely overlooked. Microvascular pericytes are in 
intimate contact with, and modulate the function of, endothelial cells. They may also 
constitute a cellular link between microvascular damage and fibrosis by transdifferentiating 
into myofibroblasts [40]. In patients with SSc, pericytes are hyperplasic [41] and activated 
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[40, 42]. Such pericytes may contribute to the overproduction of ECM molecules, and 
angiopoietin/Tie-2 signalling might be impaired. 
 
Endothelin-1 as a molecular target for intervention in the management of 
patients with SSc 
ET-1 is a highly potent vasoconstrictor that is produced by endothelial cells and is a key 
mediator of vasculopathy. ET-1 promotes cell growth, arterial wall thickening and endothelial 
cell dysfunction, resulting in decreased levels of nitric oxide. ET-1 can stimulate the 
proliferation of pulmonary artery smooth muscle cells [43, 44], fibroblast collagen 
production, the down-regulation of MMP-1 and the contraction of fibroblast-populated 
collagen lattices; all of which suggest an important role in fibrosis. Increased ET-1 
production can trigger an inflammatory cascade, elevating the plasma levels of pro-
inflammatory cytokines in patients with pulmonary arterial hypertension [45]. Thus, ET-1 
promotes vasoconstriction and contributes to cardiac and vascular hypertrophy, inflammation 
and fibrosis [46]. 
 ET-1 is over-expressed in both early- and late-stage SSc [1]. Increased expression of 
ET-1 and ET-1 receptors is detectable in pre-sclerotic and early diffuse skin lesions [47], and 
elevated levels of ET-1 have been found in the blood vessels, lungs, kidneys, and skin of SSc 
patients [48]. A role in the pathogenesis of SSc is suggested by the finding that circulating 
levels of ET-1 correlate with skin fibrosis and duration of disease [47].  
 ET-1 mediates its biological effects via the ETA and ETB receptors. ETA receptors are 
expressed by vascular smooth muscle cells and can mediate vasoconstriction, smooth muscle 
cell proliferation, fibrosis and inflammation. ETB receptors are predominantly expressed on 
endothelial cells; they can mediate vasodilation via the release of nitric oxide or potassium 
channel activation, and can remove ET-1 from the circulation. ETB receptors are also present 
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on smooth muscle cells, however in this localisation they behave similarly to ETA receptors 
[49]. 
In vasculopathic conditions such as SSc, ETB receptors are down-regulated on 
endothelial cells, which may diminish their vasodilatory role. On smooth muscle cells, ETB 
receptors are upregulated, and can contribute to cell proliferation, hypertrophy, 
inflammation, fibrosis and vasoconstriction [48, 50]. 
 
CONCLUSION 
The pathogenesis of SSc is complex and appears to involve endothelium, epithelium, 
fibroblasts and immunological mediators, resulting in dysregulated vascular remodelling and, 
ultimately, vasculopathy. Endothelial cell injury is an early and probably initiating event, but 
the precise aetiology remains unclear. There are similarities between the vasculopathies of 
different organs, including pulmonary arterial hypertension, SRC and digital ulcers, of which 
ET-1 is believed to be an important mediator. ET-1 is over-expressed in patients with SSc, 
and its serum plasma concentrations correlate with markers of disease severity. ET-1 
therefore represents an important molecular target for therapeutic intervention in the 
vascular disease manifestations of SSc. 
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Table 1: Key cytokines in the induction of the fibrosis of systemic sclerosis 
Mediator Role in fibrogenesis 
Transforming growth factor (TGF)-β Extracellular matrix (ECM) production, fibroblast proliferation and differentiation 
Connective tissue growth factor (CTGF)  
 
Regulation of fibroblast proliferation and migration and TGF-β-dependent ECM 
synthesis 
Endothelin-1 (ET-1) Regulation of ECM synthesis and contraction 
Fibroblast growth factor Regulate fibroblast growth 
Interleukin-1  Inflammatory mediator 
Interleukin-4  Regulation of collagen synthesis 
Interleukin-6  Regulator of α-smooth muscle actin expression in myofibroblasts 
Interleukin-12  Regulation of collagen synthesis 
Interleukin-13  Induction of TGF-β 
Interleukin-17  Fibroblast proliferation 
Monocyte chemoattractant protein (MCP-1) Inflammatory mediator and regulation of collagen synthesis 
MCP-3 Regulation of collagen synthesis 
Platelet derived growth factor (PDGF) Regulates TGF receptor expression, and fibroblast and progenitor cell recruitment 
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LEGENDS FOR ILLUSTRATIONS: 
Figure 1: The role of the epithelium in the pathogenesis of systemic sclerosis 
 
ET-1: endothelin-1; TGF-β: transforming growth factor beta; CTGF: 
connective tissue growth factor; BMDSC: bone marrow-derived stem cells; 
EMT: epithelial-to-mesenchymal transdifferentiation. 
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Figure 2: The role of fibroblasts in the pathogenesis of systemic sclerosis 
 
ECM: extracellular matrix. 
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Figure 3: The role of immunological mediators in the pathogenesis of systemic sclerosis 
 
IL-6: interleukin-6; Th1: T-helper cell type 1; Th2: T-helper cell type 2. 
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PROPOSED REVISED KEY MESSAGES 
 The pathogenesis of SSc involves epithelium, fibroblasts and immunological 
mediators 
 Endothelial cell damage is likely to be the initiating factor 
 Endothelin-1 is a potent mediator of vasculopathy and a therapeutic target 
 
 
 
 
 
 
